Skip to main content
VaccineWatch
VaccinesSymptomsStatesAnalysisToolsDashboardCompare

VaccineWatch

Transparent access to VAERS data for informed decision-making. We present the data as-is, with appropriate context and disclaimers.

Explore Data

  • Vaccines
  • Symptoms
  • Manufacturers
  • States
  • Dashboard
  • Compare Tool
  • Search

Deep Dives

  • The Denominator Problem
  • Onset Timing
  • Lot Number Analysis
  • COVID Impact
  • Myocarditis
  • Death Reports
  • Interactive Tools
  • All 23 Articles →

Resources

  • About
  • Methodology
  • FAQ
  • Glossary
  • Side Effects Guide
  • Vaccine Schedule
  • Vaccine Safety
  • Safety Timeline
  • Adverse Events
  • Is VAERS Reliable?
  • Report an Event
  • Disclaimer
  • VAERS Official Site ↗

Sister Sites

  • OpenMedicaid
  • OpenFeds
  • OpenSpending
  • OpenMedicare
  • OpenLobby
  • TheDataProject.ai

Data source: VAERS (Vaccine Adverse Event Reporting System)

Data through 2026 · Updated quarterly

Built by TheDataProject.ai · © 2026 VaccineWatch

Important: VAERS accepts reports of adverse events following vaccination. For any given report, there is no certainty that the reported event was caused by the vaccine. Reports may contain information that is incomplete, inaccurate, coincidental, or unverifiable. Most reports to VAERS are voluntary, which means they are subject to biases. This data cannot be used to determine if vaccines cause or contribute to adverse events.

⚠️

Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.

  1. Home
  2. Vaccines
  3. Influenza, Seasonal (Fluad Quadrivalent)
  4. Acute respiratory failure
Influenza, Seasonal (Fluad Quadrivalent)×Acute respiratory failure

Acute respiratory failure Reports for Influenza, Seasonal (Fluad Quadrivalent)

#120 most reported symptom for this vaccine

25
Reports
7
Deaths
24
Hospitalizations
28
Mortality Rate
%
96
Hosp. Rate
%

Acute respiratory failure and Influenza, Seasonal (Fluad Quadrivalent)

Acute respiratory failure has been reported 25 times in association with Influenza, Seasonal (Fluad Quadrivalent) vaccination in VAERS. This represents 0.6% of all 4,184 reports for this vaccine.

Among these reports, 7 mentioned death (28.00%) and 24 involved hospitalization (96.0%).

Acute respiratory failure is the #120 most frequently reported symptom for Influenza, Seasonal (Fluad Quadrivalent) out of 673 total symptoms.

Disclaimer: VAERS reports describe events that occurred after vaccination but do not establish that the vaccine caused the event. Many reported symptoms may be coincidental or related to underlying conditions.

What This Means

Seeing 25 reports of Acute respiratory failure after Influenza, Seasonal (Fluad Quadrivalent) vaccination may seem alarming, but context is critical.

The 28.00% mortality rate among these reports is elevated, but this reflects the severity of the condition itself rather than vaccine causation.

Important Context

•Association, not causation: These reports show Acute respiratory failure occurred after vaccination, not that the vaccine caused it.
•Background rates: Acute respiratory failure may occur naturally at baseline rates in the population, unrelated to vaccination.
•Anyone can report: VAERS accepts reports from anyone — patients, parents, healthcare providers — without requiring medical verification.
•Denominator missing: VAERS counts reports, not rates per dose. Without knowing how many doses were given, raw counts can be misleading. Learn more →

Similarly Ranked Symptoms

Atrial fibrillation25 reportsCOVID-19 pneumonia25 reportsBalance disorder24 reportsImpaired work ability24 reports

Quick Facts

Reports:25
Deaths:7
Hospitalizations:24
% of Vaccine:0.6%
Rank:#120 of 673

Related Pages

Influenza, Seasonal (Fluad Quadrivalent) OverviewAcute respiratory failure (All Vaccines)Why Raw Numbers MisleadTop Symptoms Analysis

Data Source

This data comes from the Vaccine Adverse Event Reporting System (VAERS), jointly managed by CDC and FDA.